iC9-GD2-CAR-IL-15 T-cells

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameiC9-GD2-CAR-IL-15 T-cells
Drug Alias Nameanti-GD2 CAR T-cell therapy (UNC Lineberger Comprehensive Cancer Center)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunostimulantsDisialoganglioside GD2 modulatorsT lymphocytes stimulants
TargetsDisialoganglioside GD2
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A